The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
Clarivate Analytics has released the most influential researcher list for 2018, which identifies exceptional researchers whose highly cited work is among the top 1% in their field around the world.
If you’ve ever been tested for eyeglasses, you know how one lens can create grainy, foggy images and the next crisp, clear letters. That’s the kind of difference you can see between the Gallium-68 PET/CT scan and prior technology. But are these newer imaging techniques better? And who stands to benefit most from them?
Many patients and families facing a neuroendocrine tumor (NET) diagnosis wonder if they inherited the disease from their parents or if they can pass it
What is the difference between a pancreatic neuroendocrine tumor and a pancreatic tumor? A few high profile celebrities, Aretha Franklin and Steve Jobs, have died
Early Research on Targeting Single Cancer Cells to Prevent Metastasis Despite the effectiveness of Peptide Receptor Radionuclide Therapy (PRRT) to prolong survival of those with
The Neuroendocrine Tumor Research Foundation (NETRF) gratefully received a $35,000 donation for NET research from the CarGurus Charitable Giving Fund. NETRF was nominated by a
Antibody-drug conjugate aims to combine the benefits of targeted therapy and chemotherapy Renata Jaskula-Sztul, PhD, Assistant Professor of Surgical Oncology at the University of Alabama
The National Comprehensive Cancer Network® (NCCN®) has published a brand new NCCN Guidelines for Patients focused on neuroendocrine tumor (NET). These new guidelines offer up-to-date
We are proud to welcome Brendan P. Foley, Jr. as the newest member of the NET Research Foundation Board of Directors. Brendan has been elected
NETRF has launched a $10 million fundraising campaign, the largest of its kind in our history. Every gift we receive will be MATCHED, doubling our
